Montes Archimedes Acquisition (ROIV)
(Delayed Data from NSDQ)
$16.04 USD
-0.08 (-0.50%)
Updated Oct 10, 2025 04:00 PM ET
After-Market: $16.04 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Roivant Sciences Ltd.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
ROIV 16.04 -0.08(-0.50%)
Will ROIV be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ROIV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ROIV
Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. (ROIV) is a Great Choice
Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains?
ROIV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates
Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Other News for ROIV
Is ROIV showing downside potential? MACD Bearish Signal Line Cross shows up after sinking 0.5%
ROIV rises 0.56% on October 9, leaving the technical picture intact
ROIV falls 0.56% on October 8, leaving the technical picture intact
Slingshot Bullish appears for ROIV after 0.86% move
J.P. Morgan Reaffirms Their Buy Rating on Roivant Sciences (ROIV)